Načítá se...
miR-187-3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression
Breast cancer is the most common type of malignancy in women, which remains a significant health concern worldwide. Gemcitabine is a frequently applied anticancer pharmacological agent. However, the efficacy of gemcitabine is limited by chemoresistance. In the present study, a combination of reverse...
Uloženo v:
| Vydáno v: | Exp Ther Med |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
D.A. Spandidos
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7388565/ https://ncbi.nlm.nih.gov/pubmed/32765654 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2020.8770 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|